Innovations in polycystic ovary syndrome study

Česká verzia

Authors: Jana Vrbíková
Authors place of work: Oddělení klinické endokrinologie, Endokrinologický ústav, vedoucí oddělení MUDr. Marcela Dvořáková, Ph. D.
Published in the journal: Prakt Gyn 2013; 17(3): 233-235
Category: Gynecology and Obstetrics: Review Article

Summary

The diagnostic criteria for polycystic ovary syndrome will probably change. Concerning ultrasonographic appearance of ovaries, the cut off for the number of small folicles necessary to diagnose polycystic ovary will increase. Anti Mullerian hormone could be incorporated into diagnostic criteria. Diabetes mellitus is encountered 4 times more frequently than in body mass index matched controls. Coronary heart disease and cerebrovascular disease are up to 2 times more common in polycystic ovary syndrome than in controls. Metformin led to higher number of pregnancies comparing to clomifen in non obese women.

Key words:
antimullerian hormone – coronary heart disease – diabetes mellitus type 2 – polycystic ovary syndrome – metformin

Zdroje

1. Balen AH, Laven JS, Tan SL et al. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003; 9(6): 505–514.

2. Johnstone EB, Rosen MP, Neril R et al. The polycystic ovary post-rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance. J Clin Endocrinol Metab 2010; 95(11): 4965–4972.

3. Dewailly D, Gronier H, Poncelet E et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011; 26(11): 3123–3129.

4. Lujan ME, Jarrett BY, Brooks ED et al. Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume. Hum Reprod 2013; 28(5): 1361–1368.

5. Eilertsen TB, Vanky E, Carlsen SM. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? Hum Reprod 2012; 27(8): 2494–2502.

6. Moran LJ, Misso ML, Wild RA et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010; 16(4): 347–363.

7. de Groot PC, Dekkers OM et al. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum Reprod Update 2011°17(4): 495–500.

8. Mani H, Levy MJ, Davies MJ et al. Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study. Clin Endocrinol (Oxf) 2013; 78(6): 926–934.

9. Morgan CL, Jenkins-Jones S, Currie CJ et al. Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: a retrospective, observational study. J Clin Endocrinol Metab 2012; 97(9): 3251–3260.

10. Dokras A, Clifton S, Futterweit W et al. Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis. Obstet Gynecol 2011; 117(1): 145–152.

11. Misso ML, Costello MF, Garrubba M et al. Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2013; 19(1): 2–11.